Before the emergence of dual-target strategies, several tumor-associated antigens had been explored as single CAR-T targets in triple-negative breast cancer (TNBC), among which Mesothelin (MSLN) has gained substantial attention. The gene discussed is MSLN; the disease is triple-negative breast carcinoma.